Network Bio, a biotechnology company building disease-specific AI models from human biological data to support the personalized practice of medicine, launched with $50 million in financing. Investors include Section 32, Thiel Bio, Founders Fund, Breyer Capital, Blue Venture Fund, JSL Health Capital and other life science and AI funds.